arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

enVVeno Medical Corp

NVNO

$7.05 ▼ -0.01 (-0.14%) at close

10 Visible periods

21 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

enVVeno Medical Corp faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.2M

Dividend Yield —

Revenue Growth None

Op. Margin —

ROIC -60.9% ↘

FCF / Share $-26.44 ↗

Trailing P/E —

Price / Book 0.2x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$31.24K

↓ -83.3% —

Net Income Profit after all expenses

$-19.47M

↑ +10.8% —

FCF / Share Free cash flow per share

$-26.44

↑ +23.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Revenue Growth YoY (%)	—	—	—	—	—	—	-83.3% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1141%)	-55.8% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-798%)	—	—
EPS Growth YoY (%)	25.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	-2231.4% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	13.2% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	-15.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—
Net Income Growth YoY (%)	10.8% Fair ↑ Fair Improving Year-over-year change in net income	7.2% Fair ↑ Fair Improving Year-over-year change in net income	4.7% Caution ↑ Caution Improving Year-over-year change in net income	-49.3% Weak ↓ Weak Declining Year-over-year change in net income	-80.9% Weak ↓ Weak Declining Year-over-year change in net income	-19.8% Weak ↓ Weak Declining Year-over-year change in net income	41.5% Excellent Excellent Year-over-year change in net income	-67.4% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	23.2% Good ↑ Good Improving Year-over-year change in free cash flow	-2142.5% Weak ↓ Weak Declining Year-over-year change in free cash flow	-9.6% Weak Weak Year-over-year change in free cash flow	0.4% Caution Caution Year-over-year change in free cash flow	—	—	—	—	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
FCF / Net Income (x)	0.80x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.64x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.49x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.54x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Return on Invested Capital (%)	-60.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-44.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-43.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-50.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-24.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-101.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-612.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-304.7% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	43.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-70.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-53.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-51.9% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-59.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-29.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-86.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-223.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-220.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-275.6% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-71.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-578%)	-51.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-445%)	-50.9% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-439%)	-63.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-525%)	-30.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-303%)	-128.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-958%)	—	—	70.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+367%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Interest Coverage (x)	—	—	—	-191.78x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	-8226.49x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-27.41x Weak Weak Operating income divided by interest expense Optimal: > 5x	-35.32x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-3.06M	$-1.75M	$-3.62M	$-4.55M	$-54.73M	$-9.33M	$-1.31M	$-2.74M	$-77.69K	$-56.51K

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Basic EPS, GAAP (USD)	$-33.06	$-44.53	$-1.91	$-2.20	$-1.90	—	—	—	—	—
Free Cash Flow per Share (USD)	$-26.44	$-34.44	$-1.54	$-1.40	$-1.41	—	—	—	—	—
Book Value per Share (USD)	$41.36	$84.15	$3.47	$4.09	$5.74	$2.79	$1.38	$0.17	$-1.81	—
Tangible Book Value per Share (USD)	$41.36	$84.15	$3.47	$4.09	$5.74	$2.79	$1.38	$0.12	$-1.81	—
Basic Weighted Avg Shares (shares)	589,000	490,000	12.30M	11.23M	8.68M	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Working Capital (USD)	$26.70M	$41.64M	$45.55M	$37.91M	$53.46M	$6.38M	$-452.43K	$1.31M	—	—
Total Equity (USD)	$27.13M	$42.16M	$46.20M	$38.73M	$54.40M	$7.10M	$989.94K	$2.04M	$-11.13M	$-4.22M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Sales/Revenue/Turnover (USD)	—	—	—	—	—	—	$31.24K	$186.55K	$422.11K	—
Depreciation Expense (USD)	$100.00K	$200.00K	$200.00K	$200.00K	$100.00K	$100.00K	$46.02K	$10.11K	$15.90K	—
Net Income, GAAP (USD)	$-19.47M	$-21.82M	$-23.52M	$-24.67M	$-16.53M	$-9.14M	$-7.63M	$-13.04M	$-7.79M	—
Operating Cash Flow (USD)	$-15.57M	$-16.84M	$-18.86M	$-15.62M	$-11.85M	$-7.68M	$-5.90M	$-6.36M	$-4.20M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 10 years · 40 quarters

enVVeno Medical Corp

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare NVNO with peers